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Introduction: There are no published data on standardized scoring systems for morbidity after breast
cancer surgery. Aim of the study was to establish the Clavien Dindo Classiﬁcation (CDC) as assessment
tool and to identify risk factors for morbidity after breast surgery investigating new techniques including
oncoplastic surgery and neoadjuvant chemotherapy.
Patients and methods: Between 2008 and 2010, data were retrospectively evaluated from 485 women
with breast cancer who underwent surgery at a university hospital. The CDC was used to assess the
severity of postoperative complications. Multivariable analyses were adjusted by body-mass index,
smoking, diabetes mellitus and tumour size.
Results: Overall complications (CDC 1e4) were reported in 28.7%. Second surgery related to major
complications (CDC 3e4) was mandatory in 4.7%. Axillary dissection was an independent predictor for
CDC 1e4 in all patients (P ¼ 0.008, OR of 1.81, 95%CI 1.17e2.82). We found no independent predictor for
CDC 3e4. Oncoplastic surgery increased the rate of wound infections (P ¼ 0.010, OR: 2.94, 95%CI 1.30
e6.67) and necroses (P < 0.001, OR: 8.38, 95%CI 3.28e21.4). Axillary dissection elevated wound infection
(P ¼ 0.040, OR: 2.07, 95%CI 1.03e4.14) and seroma rates (P < 0.001, OR: 2.46, 95%CI 1.51e4.01). Neo-
adjuvant chemotherapy had no impact on morbidity.
Conclusion: The CDC is a valid assessment tool for future clinical trials and may be useful for hospital
quality control. While axillary dissection and oncoplastic surgery raised morbidity, no single factor
predicted for morbidity related second surgery.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Accreditation of Breast Health Centers [1] and implementation
of multidisciplinary Health Boards [2] are assessment processes.
Health care management uses them to deﬁne standards and
improve professional performance of hospitals for two major aims:
efﬁcient patient safety and cost control. They provide data con-
cerning quality indicators as well as objective treatment evaluation
[3]. Standardization and resource economics are mandatory for
optimal cooperation of hospital management and government
systems to assure high quality services to patients. The rate of
postoperative morbidity indicates quality of surgery in Breastrgery, AKH e E 21 A, Univer-
hringer Gürtel 18-20, A-1090
0400 5641.
(P. Panhofer).
ciates Ltd. Published by Elsevier LtHealth Centers. Furthermore, major complications signiﬁcantly
raise median hospital costs [4].
Morbidity after breast surgery is low [5,6]. Novel therapies such
as neoadjuvant chemotherapy and immediate techniques of
oncoplastic surgery have increasingly been used. However, little is
known about the effect of such new techniques on postoperative
morbidity [7e9]. Moreover, standardized morbidity-measurement
tools are still lacking.
In this respect, the Clavien Dindo Classiﬁcation (CDC) is a
validated and simple classiﬁcation of surgical complications used
for general and oncologic surgery [10]. It classiﬁes the extent of
postoperative morbidity in correlation to the therapy manage-
ment. Low-Grade morbidities undergo conservative treatment,
high-Grade complications are re-operated or treated at the
Intensive Care Unit. Postoperative mortality is scored with the
highest Grade of the CDC. In summary, the Clavien Dindo Classi-
ﬁcation is therapy-oriented and may be easily adopted for onco-
logic breast surgery.d. All rights reserved.
Table 1
Clavien Dindo Classiﬁcation: morbidity in patients with breast cancer.
Grade Description of complication treatment in general Breast morbidity
Grade 1 Any deviation from the normal postoperative course without the need
for pharmacological treatment or surgical, endoscopic and radiological
interventions. Allowed therapeutic regimens are: drugs as antiemetics,
antipyretics, analgetics, diuretics and electrolytes and physiotherapy.
This Grade also includes wound infections opened at the bedside.
Abscess: 1
Bleeding: 2
Necrosis: 6 (þseroma: þ2; þlymphedema: þ1)
Seroma: 62
Wound infection: 1
Grade 2 Requiring pharmacological treatment with drugs other than such
allowed for Grade 1 complications. Blood transfusions and
total parenteral nutrition are also included.
Abscess: 5 (þseroma: þ1)
Bleeding: 6
Necrosis: 5
Seroma: 6
Wound infection: 8
(þseroma: þ17; þlymphedema: þ1)
Lung embolism: 1
Grade 3 3a: intervention not under general anaesthesia
3b: intervention under general anaesthesia
Abscess: 3 (þseroma: þ1; þnecrosis: þ3)
Bleeding: 15
Necrosis þ seroma: 1
Wound infection: 7
(þseroma: þ1; þnecrosis: þ2)
Grade 4 Life-threatening complication (including complications of the
Central Nervous System) requiring Intermediate Care/
Intensive Care Unit management
Perforation of the stomach: 1
4a: single-organ dysfunction (including dialysis)
4b: multiorgan dysfunction
Grade 5 Death of a patient Hospital mortality: 0
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CDC as tool to measure postoperative morbidity in breast cancer
surgery. Oncoplastic surgery and neoadjuvant chemotherapy as
well as other surgical parameters were assessed regarding their
relation to postoperative morbidity after adjusting for known risk
factors such as smoking [6], diabetes mellitus (DM) [6], overweight
(BMI > 35) [5,6,11] and tumour size [8,12].
2. Patients and methods
2.1. Study design
We retrospectively evaluated patients with primary breast
cancer after breast surgery and pathologically conﬁrmed R0
resection (not touching the ink) whowere treated at the Division of
General Surgery, Medical University of Vienna, between January
2008 and December 2010. Data were taken from the hospital
database. After each visit at the outpatient ward, our study nurse
prospectively processed data into a pre-existing computer work-
sheet. Data were then transferred into an Excel spreadsheet for
further statistical analyses. Patient characteristics, pathological re-
ports, treatment and follow up data have been continuously
recorded. Data were retrospectively examined and updated by the
end of 2011 with the patient information system of the Medical
University of Vienna comprising all data from patients who were
treated at the institution. The study has been approved by the local
Ethic Authorities (EK Nr 051/2011). The study was conducted ac-
cording to the criteria of Good Clinical Practice and the Declaration
of Helsinki of 1964, updated in Seoul 2008. All patients subse-
quently underwent radiotherapy in the case of breast conserving
surgery followed by chemo- and/or endocrine therapy based on
interdisciplinary tumour board decisions. Neoadjuvant chemo-
therapy was given to patients if mastectomy was primarily indi-
cated or in cases of HER-2/neu positivity or triple negativity with
tumours larger than 2 cm in diameter.
2.2. Neoadjuvant chemotherapy
Most patients received neoadjuvant chemotherapy within pro-
spective randomized trials conducted by the Austrian Breast andColorectal Cancer Study Group (ABCSG-14 and ABCSG-24) [13,14].
ABCSG-14 compared three cycles of epirubicin 75 mg/m2 and
docetaxel 75 mg/m2 (ED; on day 1, every three weeks, plus gran-
ulocyte colony-stimulating factor on days 3e10 of each cycle) to six
cycles of the same regimen as neoadjuvant treatment for breast
cancer [13]. Based upon a proposed synergistic effect of docetaxel
and capecitabine, ABCSG-24 compared three cycles of ED plus
capecitabine (EDC; epirubicin 75 mg/m2 and docetaxel 75 mg/m2
on day 1, capecitabine 1000 mg/m2 BID days 1e14, every three
weeks, plus pegﬁlgrastim 6 mg on day 2 of each cycle) with stan-
dard six cycles of ED as established in ABCSG-14. Patients with HER-
2/neu-positive disease were additionally randomized to neo-
adjuvant trastuzumab every three weeks or control [14].2.3. Surgical procedure
Indications for mastectomy included progressive carcinoma af-
ter neoadjuvant chemotherapy, multicentricity, inﬂammatory
breast cancer, unfavourable relation of tumour size and breast size
with inability to perform breast conservation with adequate mar-
gins [15] and patients’ wish. Lumpectomy with macroscopic 1 cm
free margins (microscopically not touching the ink for R0) without
skin excision was performed for breast conserving surgery. In case
of neoadjuvant chemotherapy and clinical downstaging, surgery
was performed within the new borders.
Sentinel lymph node dissection was offered to all patients with
clinically non-suspicious axilla using blue dye only. Patients after
neoadjuvant chemotherapy underwent axillary lymph node
dissection. Level I and II lymphadenectomy was carried out in the
presence of histologically veriﬁed sentinel lymph node macro-
metastasis or of palpatory suspicious lymph nodes. Non-palpable
lesions were localized preoperatively with a hook wire. These pa-
tients received perioperative antibiotic treatment with penicillin or
second-generation cephalosporin. Frozen section analyses were
routinely performed during surgery to reduce the need for second
surgery [16].
The combination of oncologic resection with plastic surgical
techniques during one surgical step (oncoplastic surgery) was
offered to some patients with a resection volume  25% [9]. We
either used the doughnut oncoplastic or other techniques of breast
Table 2
Demographic data.
Breast conserving
therapy (n ¼ 357)
Mastectomy
(n ¼ 128)
TNM
pTis 21 (5.9%) 13 (10.2%)
yT0 1 (0.3%) 0
pT1/2 330 (92.4%) 88 (68.8%)
pT3/4 5 (1.4%) 27 (21.1%)
N0 245 (68.6%) 62 (48.4%)
N0 iþa 5 (1.4%) 1 (0.8%)
N1mic 21 (5.9%) 4 (3.1%)
N1/2/3 86 (24.1%) 61 (47.7%)
G1 72 (19.6%) 6 (4.7%)
G2 166 (46.5%) 65 (50.8%)
G3/x 119 (33.3%) 57 (44.5%)
Lymph node dissection
Sentinel dissectionb 3 (2e4) 3 (2e5)
Axillary dissectionb 14 (12e19) 15 (11e18)
a Isolated tumour cells.
b Data are medians with interquartile range in parentheses.
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cision were not used in this cohort.
All patients received an axillary suction drain after sentinel
lymph node dissection or axillary dissection and an in-breast
capillary drainage after breast conservation. Patients had 2 subcu-
taneous “in-breast” suction drains after mastectomy. The main
factor for discharge was the day of removing the axillary and/or
subcutaneous “in-breast” suction drain. Before removal, it was
mandatory that the ﬂuid volume must not exceed 50 ml/24 h. As to
the in-breast capillary drainage, we used an Easy Flow with a
capillary effect. This was drawn out on the ﬁrst or second day after
surgery.
2.4. Follow up
Patients were followed up on the 10th postoperative day at the
surgical outpatient ward and during oncologic routine follow up
care. Local morbidity was recorded in our computer database
(Krankenanstalteninformationssystem ¼ KIS). Skin necrosis, axil-
lary or in-breast seroma formation, bleeding and infection with or
without abscess were evaluated. Seroma formation was deﬁned as
clinically apparent wound ﬂuid occurring after removal of the
suction drains. In general, therapy ranged from conservative
treatment with wound bandage and antibiotics up to serial seroma
punctures, abscess drainage under local anaesthesia and reopera-
tion for bleeding or large infections.
2.5. Morbidity classiﬁcation
CDC assesses the severity Grade of postoperative complications
from 1 to 5 (Table 1). Grade 0 means no complication, Grade 1e2
minor, 3e4 major morbidity and Grade 5 is related to postoperative
death [10]. The CDC was assessed retrospectively by two inde-
pendent physicians.
2.6. Statistical analyses
Categorical data were described with absolute and relative fre-
quencies. Continuous variables were described using
mean  standard deviation in the case of approximate normal
distribution and using median and interquartile range (IQR)
otherwise. The inverse KaplaneMeier method was used to calcu-
late the median follow up time. Univariate and multivariable lo-
gistic regression were employed in order to investigate the
potential effect of various established and new risk factors. Inter-
action terms of a cohort indicator (breast conserving surgery versus
mastectomy) and each risk factor were used in each model to test
for a cohort speciﬁc effect. Since none of these interaction terms
was signiﬁcant, all models contain only the main effect of the
cohort indicator and results are reported for the total data set
(breast conserving surgery and mastectomy). In the case of the
primary outcome variable, postoperative morbidity (CDC 1e4), the
high number of events allowed for a full multivariable analysis. In
contrast, the number of events for major morbidity (CDC 3e4) as
well as single complications only allowed for one adjustment var-
iable. We chose BMI which was detected as an important predictor
of postoperative morbidity in two large series [5,6]. BMI and
tumour size were log-transformed as independent variables. The
reported p-values were the results of two-sided tests. P < 0.05 was
considered statistically signiﬁcant. Due to the exploratory character
of this part of the study, no correction was performed among the
list of secondary outcomes (CDC 0e2 versus 3e4, single compli-
cations): P values and Conﬁdence Intervals (CI) are to be interpreted
accordingly. All calculations were carried out using SAS statistical
software Version 9.2 (SAS Institute Inc., Cary, NC, USA 2008).3. Results
3.1. Demographic data
TNM-status and Grading are given in Table 2. Ninety-two pa-
tients (25.8%) in the breast conserving surgery group and 47 pa-
tients (36.7%) in the mastectomy group were premenopausal. 34
patients (9.5%) before breast conserving surgery and 28 patients
(21.9%) before mastectomy underwent neoadjuvant chemotherapy.
Median follow up was 11 (IQR 1e24) months after breast
conserving surgery and 17 (IQR 4e30) months after mastectomy.
3.2. Surgical outcome
Primary surgical procedures and reoperations are presented in
Table 3. Out of 485 surgically treated patients, sentinel lymph node
dissection was done in 300 breast conserving surgery (84.0%) and
85 mastectomy (66.4%) patients. Axillary dissection was twice as
high in the mastectomy group (60.2%) compared to breast
conserving surgery patients (30.8%). oncoplastic surgery rates were
equal in both groups (breast conserving surgery: 10.9%, mastec-
tomy: 10.2%).
3.3. Postoperative morbidity and mortality
Overall, CDC 1e4 was higher in the mastectomy cohort
compared to breast conserving surgery (Table 3). Grade 1 was re-
ported in 75, Grade 2 in 41 and Grade 3 in 22 patients. Grade 4 was
related to one breast conserving surgery patient due to a non-
breast surgery-related complication (Fig. 1). Seroma rates were
twice as high in the mastectomy group compared to breast
conserving surgery. Two patients, one in each cohort, suffered from
a chronic lymph oedema after axillary dissection at one-year follow
up. Detailed morbidity data after axillary dissection, oncoplastic
surgery and neoadjuvant chemotherapy are presented in Table 3.
Second surgery was mandatory in 106 patients (21.9%). Major
postoperative complications (CDC 3e4) were treated surgically in 5
mastectomy and 18 breast conserving surgery patients (Fig. 1). 50
patients (10.3%) were reoperated due to inadequate tumour exci-
sion. Re-excision was reported in one patient (1/128: 0.8%) after
primary mastectomy and in 29 breast conserving surgery patients
(29/357: 8.1%). 20 patients (20/485: 4.1%) had to undergo mastec-
tomy after prior breast conserving surgery due to residual disease.
Isolated axillary dissection as second surgery was performed in 10
Table 3
Morbidity data.
Patients Axillary dissection Oncoplastic surgery Neoadjuvant chemotherapy
(n ¼ 485) Yes No Yes No Yes No
Breast conservation n ¼ 357 n ¼ 110 n ¼ 247 n ¼ 39 n ¼ 318 n ¼ 34 n ¼ 323
Overall morbidity (CDCa 1e4) 88 (24.6%) 40 (36.4%) 48 (19.4%) 12 (30.8%) 76 (23.9%) 8 (23.5%) 80 (24.8%)
Seroma 52 (14.6%) 28 (25.5%) 24 (9.7%) 5 (12.8%) 47 (14.8%) 6 (17.6%) 46 (14.2%)
Wound infection 28 (7.8%) 14 (12.7%) 14 (5.7%) 6 (15.4%) 22 (6.9%) 3 (8.8%) 25 (7.7%)
Necrosis 10 (2.8%) 6 (5.5%) 4 (1.6%) 4 (10.3%) 6 (1.9%) 0 10 (3.1%)
Bleeding 14 (3.9%) 5 (4.6%) 9 (3.6%) 2 (5.1%) 12 (3.8%) 0 14 (4.3%)
Abscess 13 (3.6%) 4 (3.6%) 9 (3.6%) 2 (5.1%) 11 (3.5%) 1 (2.9%) 12 (3.7%)
Mastectomy n ¼ 128 n ¼ 77 n ¼ 51 n ¼ 13 n ¼ 115 n ¼ 28 n ¼ 100
Overall morbidity (CDCa 1e4) 51 (39.8%) 33 (42.9%) 18 (35.3%) 8 (61.5%) 43 (37.4%) 13 (46.4%) 38 (38.0%)
Seroma 39 (30.5%) 27 (35.1%) 12 (23.5%) 4 (30.8%) 35 (30.4%) 11 (39.3%) 28 (28.0%)
Wound infection 9 (7.0%) 6 (7.8%) 3 (5.9%) 3 (23.1%) 6 (5.2%) 1 (3.6%) 8 (8.0%)
Necrosis 10 (7.8%) 5 (6.5%) 5 (9.8%) 5 (38.5%) 5 (4.3%) 1 (3.6%) 9 (9.0%)
Bleeding 5 (3.9%) 3 (3.9%) 2 (3.9%) 1 (7.7%) 4 (3.5%) 1 (3.6%) 4 (4.0%)
Abscess 1 (0.8%) 0 1 (2.0%) 1 (7.7%) 0 0 1 (1.0%)
a Clavien Dindo Classiﬁcation.
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(4.7%) underwent reoperation of the breast in combination with
axillary dissection after false negative sentinel lymph node
dissection dissection. There was no case of postoperative in-
hospital mortality (CDC 5).3.4. Risk factors for postoperative morbidity
In the univariate analysis, axillary dissection (P ¼ 0.001, OR:
1.99), tumour size (P ¼ 0.021, OR: 1.26 for each doubling of tumour
size) and BMI (P ¼ 0.001, OR: 3.58 for each doubling of BMI) pre-
dicted for postoperative morbidity (CDC 1e4). In the multivariable
model, the effects of axillary dissection, oncoplastic surgery and
neoadjuvant chemotherapy were adjusted for each other and for
known risk factors. Axillary dissection was the only risk factor to
show a clinically relevant and statistically signiﬁcant effect on CDC
1e4 (Table 4). Furthermore, axillary dissection was a predictor of
wound infections and seroma rates. Oncoplastic surgery predicted
increased wound infection and necrosis rates (Table 4). All necroses
were limited to the cutaneous and subcutaneous layer, no ﬂapCDC 0: 60.2
CDC 0: 75.4
CDC 1: 24.2
CDC 1: 12.3
CDC 2: 11.7CDC 2: 7.3
CDC 3: 3.9CDC 3: 4.8
CDC 4: 0.3
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Breast conservation Mastectomy
Fig. 1. Clavien Dindo Classiﬁcation (CDC) grading (0 ¼ no complication;
5 ¼ postoperative mortality) in patients undergoing breast conserving surgery
(n ¼ 357) and mastectomy (n ¼ 128). Data are presented as percentages.necroses were reported. The effect of each risk factor on the
considered complications can be quantiﬁed by an odds ratio for the
total set of patients (i.e. breast conserving surgery and mastec-
tomy), since the effects were not signiﬁcantly modiﬁed by dis-
tinguishing between the two cohorts (breast conserving surgery
versus mastectomy).
4. Discussion
This is the ﬁrst published report about using a modiﬁed CDC
score to evaluate postoperative morbidity in breast cancer patients.
After adjusting for known risk factors (obesity, diabetes mellitus,
smoking and tumour size) our analyses demonstrated that axillary
dissection was the only independent risk factor for the develop-
ment of postoperative morbidity (CDC 1e4), especially related to
seroma formation. Necrosis was increased after oncoplastic sur-
gery. Both axillary dissection and oncoplastic surgery were asso-
ciated with elevated wound infection rates. Other factors such as
neoadjuvant chemotherapy failed to show a signiﬁcant impact in
multivariable analyses. Moreover, no potential risk factor was
identiﬁed for complication related reoperations (CDC 3).
Reported morbidity rates after breast surgery range from 2%
[5,6] to 35% [17]. This major discrepancy between the reported
studies may be due to different assessment methods andmorbidity
deﬁnition. In order to standardize morbidity measurement, we
incorporated the CDC for breast cancer patients. The CDC helps to
compare datawithin different surgical departments [10]. It uses the
complication treatment for classifying morbidity. Complications,
especially minor ones, are frequently not precisely documented.
Complication treatment, however, is documented well and based
on hard facts. Furthermore, it is not inﬂuenced by subjective
interpretation; therefore morbidity treatment documentation
represents an objective tool for standardized scoring [10].
The Doc-Cert AG St. Gallen certiﬁcation program for Breast
Health Centers surveys morbidity data in only 2 (wound infection,
post-radiation skin reactions) out of 34 items. According to the
EUSOMA certiﬁcation, requirements for accreditation include
documentation of lymph oedema [18]. Standardized and sufﬁcient
evaluation of postoperative complications is lacking in those cer-
tiﬁcation programs. The use of a modiﬁed CDC in breast cancer
patients was practical in our study. We suggest using this classiﬁ-
cation for further studies and in the certiﬁcation process for Breast
Health Centers. Morbidity data of different centers, even using
different certiﬁcation programs, could be compared with each
other as important quality measure.
Table 4
Multivariable analysis of risk factors for postoperative morbidity and morbidity related reoperations.
Patients Axillary dissection P value Oncoplastic surgery P value Neoadjuvant chemotherapy P value
(n ¼ 485) OR [95% CI] OR [95% CI] OR [95% CI]
Overall morbidity
(CDCa 1e4) 139 (28.7%) 1.88 [1.18e2.98] 0.008 1.72 [0.91e3.23] 0.094 0.86 [0.45e1.64] 0.649
Reoperations
(CDCa 3e4) 23 (4.7%) 0.88 [0.37e2.11] 0.775 1.88 [0.65e5.45] 0.245 0.48 [0.09e2.54] 0.387
Seroma 91 (18.8%) 2.46 [1.51e4.01] <0.001 0.92 [0.43e1.98] 0.836 1.51 [0.79e2.88] 0.216
Wound infection 37 (7.6%) 2.07 [1.03e4.14] 0.040 2.94 [1.30e6.67] 0.010 1.07 [0.37e3.07] 0.902
Necrosis 20 (4.1%) 1.49 [0.60e3.70] 0.386 8.38 [3.28e21.40] <0.001 0.40 [0.07e2.17] 0.287
Bleeding 19 (3.9%) 1.15 [0.44e3.04] 0.772 1.96 [0.60e6.46] 0.268 0.19 [0.01e3.15] 0.249
Abscess 14 (2.9%) 0.81 [0.27e2.48] 0.718 2.34 [0.68e8.02] 0.178 1.11 [0.20e6.11] 0.904
Odds ratio: overall morbidity is adjusted for body-mass index, smoking, diabetes mellitus and tumour size, all other risk factors are adjusted solely for body-mass index.
a Clavien Dindo Classiﬁcation: CDC 4: one patient underwent reoperation and stayed at the intensive care unit afterwards.
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axillary dissection even if macrometastases were found within the
sentinel lymph node [19]. That paradigm shift has been discussed
very controversially. Our data support the notion to omit axillary
dissection in respect to morbidity. Axillary dissection was the only
independent risk factor for elevated morbidity due to seroma and
infection rates. Elevated seroma accumulations facilitate the
emergence of wound infections. Other authors conﬁrmed higher
morbidity rates after axillary dissection compared to sentinel
lymph node dissection. Axillary dissection mainly leads to early
complications, while delayed morbidity and second surgery rates
were not increased [20].
In future, modern devices such as bipolar vessel-sealing devices
(Ligasure) may reduce seroma formation and make axillary
dissection safer [21]. Reduced seroma amounts with shorter
drainage periods and sufﬁcient sanitation standards in the opera-
tion and hospital wards can minimize infection rates. Our data do
not answer the question about long term morbidity and thus these
data should not lead to support omitting axillary dissection in
general.
Patients undergoing oncoplastic surgery have longer scars and
more extensive mobilization of the breast parenchyma. The blood
supply is hampered by preparation and the larger wound surface
may promotemorbidity which has been demonstrated in up to 25%
of these patients [22,23]. In the literature, necrosis rates range
between 16% and 25% [7,9,22,24] and delayed wound healing be-
tween 19% and 25% [23,25]. In our cohort, oncoplastic surgery
raised wound infections and necrosis rates signiﬁcantly without
increasing second surgery rates. Delayed wound healing and
extensive wounds may promote tissue infection. Therefore, strin-
gent sterility in the operation theatre and standardized antibiotic
prophylaxis are mandatory. Usually necrosis is seen at the edges of
the breast skin ﬂaps. This may be further reduced by careful
dissection, leaving a thicker subcutaneous tissue in place. In the
future, we hope that necrosis rates may be signiﬁcantly reduced by
applying new agents like Traditional Chinese Medicine herbal
therapy [26].
Cytotoxic agents have shown to suppress immune function and
wound healing in animal testing [27,28]. Shamberger et al. reported
that a prolonged interval of cytostatic therapy followed by surgery
signiﬁcantly reduced morbidity [28]. Donker et al. compared pa-
tients with skin-sparing mastectomy and immediate prosthetic
reconstruction who had undergone neoadjuvant chemotherapy
versus no neoadjuvant chemotherapy [29]. Seroma rates were
equal in both cohorts, whereas skin necrosis rates were signiﬁ-
cantly higher in the control group without neoadjuvant chemo-
therapy. That outcome might be explained by the younger age of
patients undergoing neoadjuvant chemotherapy. Broadwater et al.
compared similar cohorts of women undergoing mastectomy [30].Postoperative morbidity was equal in both groups, but seroma rates
were signiﬁcantly decreased in the neoadjuvant chemotherapy
group compared to the control patients. The authors did not give
any explanation for those data. In general, several other authors
investigating morbidity after breast surgery failed to ﬁnd signiﬁ-
cant differences comparing patients with and without neoadjuvant
chemotherapy [8,11]. In our study, neoadjuvant chemotherapy was
associated neither to increased postoperative morbidity nor higher
second surgery rates.
There are several biases in our study. First, the low event rates
reduce the power of the multivariable analyses. Second, patients
who had a prolonged hospital stay due to a longer drainage period
were not included in the morbidity assessment. Those patients
usually underwent neoadjuvant chemotherapy. Although there are
data showing that longer drainage periods do not reduce seroma
formationwe still believe that the increased seroma formation after
neoadjuvant chemotherapy seen in our personal praxis is thus not
reﬂected in our trial.
In conclusion, the Clavien Dindo Classiﬁcation may be recom-
mended to document morbidity as part of certiﬁcation programs
for Breast Health Centers. However, this classiﬁcation has to be re-
evaluated within another patient cohort.Ethical approval
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